Softwr

Healthcare · head to head

Therapixel vs Woebot Health

Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite
Woebot Health logo

Woebot Health

Healthcare

Conversational CBT chatbot that withdrew from consumer distribution and now sells only to payers and providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.; Woebot Health the company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • They diverge on capability: Therapixel covers MammoScreen 2D, Woebot Health covers Scripted CBT dialogue.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Therapixel and Woebot Health actually diverge.

Attributes where Therapixel and Woebot Health differ
AttributeTherapixelWoebot Health
PlatformsWebiOS, Android, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

Only in Woebot Health

  • Scripted CBT dialogue
  • Mood tracking
  • Crisis routing
  • Between-session support
  • Payer deployment
  • Provider copilot positioning
  • Research licensing
  • Population reporting

What people use each for

The jobs each tool is most often brought in to do.

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Woebot Health
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Woebot Health
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Woebot Health
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Woebot Health

Woebot Health

  • A health plan wanting a low intensity behavioural health option for members on a waiting list for therapynot Therapixel
  • A provider organisation offering structured between-session CBT practice to patients already in treatmentnot Therapixel
  • A research group running a trial that needs a clinically scripted rather than generative conversational agent for safety reasonsnot Therapixel
  • A payer targeting a specific population such as postpartum members where scripted CBT content already existsnot Therapixel

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Woebot Health

  • The company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • It is not an FDA cleared treatment for any indication, so it cannot be positioned to members as therapy and cannot substitute for a covered behavioural health benefit.
  • The scripted, non-generative design that makes it safe also makes it feel rigid next to current conversational AI, and engagement drops off quickly once users hit the edges of the script.
  • Published evidence is short-horizon symptom change in selected populations, mostly young adults, with little evidence of durable benefit or effect at whole-population scale.
  • With consumer distribution gone, the remaining business depends on a small number of payer and provider contracts, so a buyer should assume real vendor continuity risk over a multi-year term.

Pricing, plan by plan

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Woebot Health

On request
  • Woebot for payers and providers$undefined/year
    • Contracted per member per month or as a population licence
    • Sold to health plans and provider organisations, not to employers or individuals
    • No consumer purchase route since the app closed in June 2025

Which should you pick?

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Choose Woebot Health if

  • You need scripted cbt dialogue.
  • You work on iOS, Android, Web.
  • You also want mood tracking.
Woebot Health review

Questions people ask

Is Therapixel or Woebot Health better?
Neither clearly leads. Therapixel starts at On request and Woebot Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Therapixel or Woebot Health?
Therapixel starts at On request and Woebot Health at On request.
Does Therapixel or Woebot Health run on more platforms?
Therapixel runs on Web. Woebot Health runs on iOS, Android, Web.
What is Therapixel best used for?
Therapixel is most often used for a european breast screening programme running mandatory double reading that wants to evaluate ai as a concurrent or second reader within what national guidance permits, an american breast centre that has moved to tomosynthesis and needs reading support on dbt specifically, which therapixel holds a clearance for, a screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own threshold, a radiology group evaluating multiple mammography ai vendors head to head on their own historic case set before committing. Of those, a european breast screening programme running mandatory double reading that wants to evaluate ai as a concurrent or second reader within what national guidance permits and an american breast centre that has moved to tomosynthesis and needs reading support on dbt specifically, which therapixel holds a clearance for are not what Woebot Health is typically brought in for.
What can Therapixel do that Woebot Health cannot?
Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report. Woebot Health covers Scripted CBT dialogue, Mood tracking, Crisis routing, Between-session support.

Answered from the vendors’ own pages

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Woebot Health: Is Woebot still available?

Not to consumers. The consumer app closed in June 2025. The company continues to offer the product to payers, providers and researchers.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Woebot Health: Is it FDA cleared?

No. It held Breakthrough Device designation but never obtained marketing authorisation, and the founder cited the cost of that pathway as the reason for closing the consumer app.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Woebot Health: Is it generative AI?

Historically no. The dialogue is clinician-written and rule-based, a deliberate safety choice that limits how naturally it converses.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Woebot Health: What does the evidence show?

Randomised studies reported reduced depressive symptoms over short periods in selected populations, notably young adults. That is symptom change in a trial, not demonstrated population outcomes.

Share

Related pages

More on Therapixel

More on Woebot Health

Keep looking

Other head to heads